South Korea · Delayed Price · Currency is KRW BCWORLD PHARM. Statistics
Total Valuation
BCWORLD PHARM. has a market cap or net worth of KRW 41.59 billion. The enterprise value is 123.16 billion.
| Market Cap | 41.59B |
| Enterprise Value | 123.16B |
Important Dates
The last earnings date was Friday, March 27, 2026.
| Earnings Date | Mar 27, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
BCWORLD PHARM. has 9.28 million shares outstanding. The number of shares has increased by 0.20% in one year.
| Current Share Class | 9.28M |
| Shares Outstanding | 9.28M |
| Shares Change (YoY) | +0.20% |
| Shares Change (QoQ) | -36.33% |
| Owned by Insiders (%) | 43.24% |
| Owned by Institutions (%) | n/a |
| Float | 5.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.55 |
| PB Ratio | 0.57 |
| P/TBV Ratio | 0.60 |
| P/FCF Ratio | 26.17 |
| P/OCF Ratio | 7.46 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.38, with an EV/FCF ratio of 77.50.
| EV / Earnings | -25.15 |
| EV / Sales | 1.62 |
| EV / EBITDA | 12.38 |
| EV / EBIT | 61.68 |
| EV / FCF | 77.50 |
Financial Position
The company has a current ratio of 0.55, with a Debt / Equity ratio of 1.20.
| Current Ratio | 0.55 |
| Quick Ratio | 0.30 |
| Debt / Equity | 1.20 |
| Debt / EBITDA | 8.76 |
| Debt / FCF | 54.85 |
| Interest Coverage | 0.47 |
Financial Efficiency
Return on equity (ROE) is -4.23% and return on invested capital (ROIC) is 1.31%.
| Return on Equity (ROE) | -4.23% |
| Return on Assets (ROA) | 0.71% |
| Return on Invested Capital (ROIC) | 1.31% |
| Return on Capital Employed (ROCE) | 2.29% |
| Weighted Average Cost of Capital (WACC) | 5.49% |
| Revenue Per Employee | 270.71M |
| Profits Per Employee | -17.49M |
| Employee Count | 280 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 2.50 |
Taxes
In the past 12 months, BCWORLD PHARM. has paid 931.28 million in taxes.
| Income Tax | 931.28M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +9.76% in the last 52 weeks. The beta is 0.85, so BCWORLD PHARM.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.85 |
| 52-Week Price Change | +9.76% |
| 50-Day Moving Average | 5,075.80 |
| 200-Day Moving Average | 4,477.66 |
| Relative Strength Index (RSI) | 37.70 |
| Average Volume (20 Days) | 11,427 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BCWORLD PHARM. had revenue of KRW 75.80 billion and -4.90 billion in losses. Loss per share was -527.00.
| Revenue | 75.80B |
| Gross Profit | 30.54B |
| Operating Income | 2.00B |
| Pretax Income | -2.21B |
| Net Income | -4.90B |
| EBITDA | 9.95B |
| EBIT | 2.00B |
| Loss Per Share | -527.00 |
Balance Sheet
The company has 6.81 billion in cash and 87.16 billion in debt, with a net cash position of -80.35 billion or -8,656.62 per share.
| Cash & Cash Equivalents | 6.81B |
| Total Debt | 87.16B |
| Net Cash | -80.35B |
| Net Cash Per Share | -8,656.62 |
| Equity (Book Value) | 72.50B |
| Book Value Per Share | 10,949.86 |
| Working Capital | -40.64B |
Cash Flow
In the last 12 months, operating cash flow was 5.58 billion and capital expenditures -3.99 billion, giving a free cash flow of 1.59 billion.
| Operating Cash Flow | 5.58B |
| Capital Expenditures | -3.99B |
| Depreciation & Amortization | 7.95B |
| Net Borrowing | -2.50B |
| Free Cash Flow | 1.59B |
| FCF Per Share | 171.20 |
Margins
Gross margin is 40.29%, with operating and profit margins of 2.63% and -6.46%.
| Gross Margin | 40.29% |
| Operating Margin | 2.63% |
| Pretax Margin | -2.92% |
| Profit Margin | -6.46% |
| EBITDA Margin | 13.12% |
| EBIT Margin | 2.63% |
| FCF Margin | 2.10% |
Dividends & Yields
This stock pays an annual dividend of 90.91, which amounts to a dividend yield of 2.03%.
| Dividend Per Share | 90.91 |
| Dividend Yield | 2.03% |
| Dividend Growth (YoY) | 10.00% |
| Years of Dividend Growth | 2 |
| Payout Ratio | n/a |
| Buyback Yield | -0.20% |
| Shareholder Yield | 1.84% |
| Earnings Yield | -11.77% |
| FCF Yield | 3.82% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 29, 2025. It was a forward split with a ratio of 1.1.
| Last Split Date | Dec 29, 2025 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
BCWORLD PHARM. has an Altman Z-Score of 0.71 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.71 |
| Piotroski F-Score | 6 |